RNA-Seq Explores the Mechanism of Oxygen-Boosted Sonodynamic Therapy Based on All-in-One Nanobubbles to Enhance Ferroptosis for the Treatment of HCC
Yichi Chen,Haitao Shang,Chunyue Wang,Jiaqi Zeng,Shentao Zhang,Bolin Wu,Wen Cheng
DOI: https://doi.org/10.2147/IJN.S343361
IF: 7.033
2022-01-07
International Journal of Nanomedicine
Abstract:Yichi Chen, 1 Haitao Shang, 1 Chunyue Wang, 1 Jiaqi Zeng, 2 Shentao Zhang, 1 Bolin Wu, 1, 3 Wen Cheng 1, 3 1 Department of Ultrasound, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China; 2 School of Life Science and Technology, Computational Biology Research Center, Harbin Institute of Technology, Harbin, People's Republic of China; 3 Department of Interventional Ultrasound, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China Correspondence: Wen Cheng; Bolin Wu Department of Ultrasound, Harbin Medical University Cancer Hospital, No. 150, Haping Road, Nangang District, Harbin, Heilongjiang Province, 150081, People's Republic of China Tel +86 13313677182 ; +86 15663615088 Fax +86 451 85718392 ; +86 451 86298651 Email ; Background: The combination of sonodynamic therapy and oxygenation strategy is widely used in cancer treatment. However, due to the complexity, heterogeneity and irreversible hypoxic environment produced by hepatocellular carcinoma (HCC) tissues, oxygen-enhancing sonodynamic therapy (SDT) has failed to achieve the desired results. With the emergence of ferroptosis with reactive oxygen species (ROS) cytotoxicity, this novel cell death method has attracted widespread attention. Methods: In this study, nanobubbles (NBs) were connected with the sonosensitizer Indocyanine green (ICG) to construct a 2-in-1 nanoplatform loaded with RAS-selective lethal (RSL3, ferroptosis promoter) ( NBs), combined with oxygen-enhanced SDT and potent ferroptosis. In addition, nanobubbles (NBs) combined with low-frequency ultrasound (LFUS) are called ultrasound-targeted nanobubble destruction (UTND) to ensure specific drug release and improve safety. Results: MDA/GSH and other related experimental results show that NBs can enhance SDT and ferroptosis. Through RNA sequencing (RNA-seq), the differential expression of LncRNA and mRNA before and after synergistic treatment was identified, and then GO and KEGG pathways were used to enrich and analyze target genes and pathways related ferroptosis sensitivity. We found that they were significantly enriched in the ferroptosis-related pathway MAPK cascade and cell proliferation. Then, we searched for the expression of differentially expressed genes in the TCGA Hepatocellular carcinoma cohort. At the same time, we evaluated the proportion of immune cell infiltration and the identification of co-expression network modules and related prognostic analysis. We found that it was significantly related to the tumor microenvironment of hepatocellular carcinoma. The prognostic risk genes "SLC37A2" and "ITGB7" may represent new hepatocellular carcinoma ferroptosis-inducing markers and have guiding significance for treating hepatocellular carcinoma. Conclusion: The therapeutic effect of the in vitro synergistic treatment has been proven to be significant, revealing the prospect of 2-in-1 nanobubbles combined with SDT and ferroptosis in treating HCC. Keywords: ferroptosis, sonodynamic therapy, HCC, RSL3, synergistic therapy Graphical Hepatocellular carcinoma, as the fourth cancer incidence, has been the fastest-rising cause of cancer-related deaths worldwide. 1 There are approximately 840,000 new cases of HCC each year, and at least 780,000 people die from HCC. 2 The main treatment for liver cancer is surgical resection, liver transplantation, local radiotherapy and chemotherapy. 3 However, due to the invisibility of the onset of HCC and the lack of specific early markers, most patients are usually diagnosed as advanced HCC, 4 the above treatment methods cannot get a thorough treatment, and sorafenib has been the mainstream targeted therapy for advanced HCC. However, drug resistance gradually develops in the later stages of treatment. 5,6 According to reports, sorafenib is mainly causing cell ferroptosis to achieve antitumor, and the role of apoptosis in sorafenib resistance in HCC has been demonstrated. 7 Induce ferroptosis and increase the sensitivity of ferroptosis, avoid apoptosis, effectively improve the treatment of hepatocellular carcinoma, and reduce the occurrence of drug resistance. 8 Many nanomedicines have been invented for HCC and rodent hepatoma model treatment. 9–11 In addition, some nanocapsules could also promote chemotherapy and induce an immune response, which synergistically performed antitumor efficacy. 12–14 Ferroptosis was first proposed as a novel type of cell death in 2012. 15,16 Unlike other apoptotic and non-apoptotic death forms, iron and lipid peroxides are the two m -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology